The Impact of Vedolizumab and Ustekinumab on Articular Extra-Intestinal Manifestations in Inflammatory Bowel Disease Patients: A Real-Life Multicentre Cohort Study.

Cara De GalanMarie TruyensHarald PeetersFrancisco Mesonero GismeroAinara ElorzaPaola TorresLiv VandermeulenAranzazu Jauregui AmezagaRocio Ferreiro-IglesiasTom HolvoetYamile ZabanaLaia Peries ReverterGerard Bryan GonzalesJeroen GeldofGaëlle VarkasMartine De VosTriana Lobatón

Published in: Journal of Crohn's & colitis (2022)

Vedolizumab and ustekinumab can be used safely in patients with articular extra-intestinal manifestations. Only a temporary increased risk for developing arthralgia has been observed under vedolizumab.

Keyphrases

ulcerative colitis
patients with inflammatory bowel disease
end stage renal disease
ejection fraction
newly diagnosed
clinical trial
prognostic factors
peritoneal dialysis
study protocol
patient reported outcomes